147 related articles for article (PubMed ID: 11028832)
21. Treatment of fibromyalgia with tropisetron--dose and efficacy correlations.
Späth M; Stratz T; Färber L; Haus U; Pongratz D
Scand J Rheumatol Suppl; 2004; 119():63-6. PubMed ID: 15515418
[TBL] [Abstract][Full Text] [Related]
22. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience.
Kohnen R; Färber L; Späth M
Scand J Rheumatol Suppl; 2004; 119():67-71. PubMed ID: 15515419
[TBL] [Abstract][Full Text] [Related]
23. [5-HT3-receptor-antagonists in therapy of rheumatic diseases].
Müller W; Stratz T
Z Rheumatol; 2003 Feb; 62(1):39-41. PubMed ID: 12624802
[No Abstract] [Full Text] [Related]
24. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome.
Seidel MF; Weinreich GF; Stratz T; Müller W
Rheumatol Int; 2007 Sep; 27(11):1025-30. PubMed ID: 17634903
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children.
Gaedicke G; Erttmann R; Henze G; Hartmann W; Drechsler S; Grass P; Faerber L; Kutz K
Pediatr Hematol Oncol; 1996; 13(5):405-16. PubMed ID: 10897812
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group.
Ferrari MD; Wilkinson M; Hirt D; Lataste X; Notter M;
Pain; 1991 Jun; 45(3):283-291. PubMed ID: 1876437
[TBL] [Abstract][Full Text] [Related]
27. Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron.
Stratz T; Müller W
Scand J Rheumatol Suppl; 2004; 119():59-62. PubMed ID: 15515417
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
Wolf H
Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
[TBL] [Abstract][Full Text] [Related]
29. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder.
Lecrubier Y; Puech AJ; Azcona A; Bailey PE; Lataste X
Psychopharmacology (Berl); 1993; 112(1):129-33. PubMed ID: 7871001
[TBL] [Abstract][Full Text] [Related]
30. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
Müller W; Stratz T
Scand J Rheumatol Suppl; 2004; 119():44-8. PubMed ID: 15515413
[TBL] [Abstract][Full Text] [Related]
31. Treatment of chronic low back pain with tropisetron.
Stratz T; Müller W
Scand J Rheumatol Suppl; 2004; 119():76-8. PubMed ID: 15515421
[TBL] [Abstract][Full Text] [Related]
32. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice.
Tolk J; Kohnen R; Müller W
Scand J Rheumatol Suppl; 2004; 119():72-5. PubMed ID: 15515420
[TBL] [Abstract][Full Text] [Related]
33. Influence of tropisetron on the serum substance P levels in fibromyalgia patients.
Stratz T; Fiebich B; Haus U; Müller W
Scand J Rheumatol Suppl; 2004; 119():41-3. PubMed ID: 15515412
[TBL] [Abstract][Full Text] [Related]
34. [What's new in the therapy of fibromyalgia?].
Späth M
Schmerz; 2003 Dec; 17(6):437-40. PubMed ID: 14648317
[TBL] [Abstract][Full Text] [Related]
35. Serotonin type 3 receptor antagonist tropisetron in the treatment of chronic inflammatory rheumatic conditions--preliminary clinical experience.
Hrycaj P
Scand J Rheumatol Suppl; 2004; 119():55-8. PubMed ID: 15515416
[TBL] [Abstract][Full Text] [Related]
36. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone.
Samborski W; Stratz T; Mackiewicz S; Müller W
Scand J Rheumatol Suppl; 2004; 119():51-4. PubMed ID: 15515415
[TBL] [Abstract][Full Text] [Related]
37. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.
Vergne-Salle P; Dufauret-Lombard C; Bonnet C; Simon A; Trèves R; Bonnabau H; Bertin P
Eur J Pain; 2011 May; 15(5):509-14. PubMed ID: 21036635
[TBL] [Abstract][Full Text] [Related]
38. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
39. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
40. The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation.
Or R; Drakos P; Nagler A; Naparstek E; Kapelushnik J; Cass Y
Support Care Cancer; 1994 Jul; 2(4):245-8. PubMed ID: 8087443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
